Overview

An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate sustained virologic response 12 weeks after the end of treatment (SVR12) following 12 weeks of simeprevir plus sofosbuvir with and without ribavirin (RBV) and 24 weeks of simeprevir plus sofosbuvir without RBV in post orthotopic liver transplant participants with recurrent hepatitis (inflammation of the liver) C virus (HCV) Genotype 1 infection.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Scientific Affairs, LLC

Treatments:

Ribavirin
Simeprevir
Sofosbuvir